Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease

Fabio Blandini, Giuseppe Nappi, J. Timothy Greenamyre

Research output: Contribution to journalArticle

Abstract

Using permanent cannulas connected to subcutaneous pumps, we infused selective glutamate antagonists into the subthalamic nucleus of rats. Pumps were implanted immediately after the intrastriatal injection of 6-hydroxydopamine and delivered micro-quantities of the N-methyl-D-aspartate antagonist MK-801 or the α-amino-3-hydroxy-5-methylisoxazole antagonist NBQX for 4 weeks. Subthalamic infusion of MK-801, but not of NBQX, prevented the basal ganglia metabolic changes and motor abnormalities caused by nigrostriatal lesion. Animals treated with MK-801 also exhibited marked reduction of nigral cell loss. We conclude that pharmacological modulation of subthalamic activity may have both symptomatic and neuroprotective effects in Parkinson's disease.

Original languageEnglish
Pages (from-to)525-529
Number of pages5
JournalAnnals of Neurology
Volume49
Issue number4
DOIs
Publication statusPublished - 2001

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease'. Together they form a unique fingerprint.

  • Cite this